Spots Global Cancer Trial Database for asp2215
Every month we try and update this database with for asp2215 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | NCT02310321 | Acute Myeloid L... FLT3-mutated Ac... | gilteritinib Idarubicin Cytarabine | 18 Years - 69 Years | Astellas Pharma Inc | |
| A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | NCT02752035 | Acute Myeloid L... Acute Myeloid L... | gilteritinib azacitidine | 18 Years - | Astellas Pharma Inc | |
| Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02181660 | Acute Myeloid L... | Gilteritinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | NCT03730012 | Acute Myeloid L... Acute Myeloid L... | gilteritinib atezolizumab | 18 Years - | Astellas Pharma Inc | |
| Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | NCT03409081 | Acute Myeloid L... FMS-like Tyrosi... | gilteritinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02236013 | Acute Myeloid L... | Gilteritinib Idarubicin Cytarabine Daunorubicin | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | NCT03182244 | Acute Myeloid L... | gilteritinib LoDAC (Low Dose... MEC (Mitoxantro... FLAG (Granulocy... | 18 Years - | Astellas Pharma Inc | |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | NCT03070093 | Acute Myeloid L... FMS-like Tyrosi... | gilteritinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02236013 | Acute Myeloid L... | Gilteritinib Idarubicin Cytarabine Daunorubicin | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | NCT02495233 | Non-Small-Cell ... | Gilteritinib Erlotinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | NCT02495233 | Non-Small-Cell ... | Gilteritinib Erlotinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | NCT02997202 | Acute Myeloid L... | gilteritinib Placebo | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | NCT03182244 | Acute Myeloid L... | gilteritinib LoDAC (Low Dose... MEC (Mitoxantro... FLAG (Granulocy... | 18 Years - | Astellas Pharma Inc | |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | NCT02456883 | Advanced Solid ... Pharmacokinetic... | gilteritinib 14C-labeled gil... | 18 Years - | Astellas Pharma Inc | |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | NCT03070093 | Acute Myeloid L... FMS-like Tyrosi... | gilteritinib | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
